

DECEMBER 2024



Merry Christmas & Happy New Year!

FROM ALL OF US AT IMAGING BIOMETRICS



Updates and Accolades



Welcoming a Trailblazer in Brain Tumor Advocacy and Research

We'd like to welcome Dr. Al Musella to the IQ-AI board as a non-executive director. Dr.

Musella brings almost three decades of experience as founder and president of the Musella Foundation for Brain Tumor Research and Information Inc. Dr. Musella formed the first online support group for brain tumor patients in 1993, which has since evolved into the website, virtualtrials.org.



PROACTIVE
INTERVIEW

[View here](#)



IB Updates Agreement with GE Healthcare

Announcing an agreement with GE Healthcare, which streamlines the distribution of Imaging Biometrics' IB Neuro and IB Delta T1 platforms! [View article](#)




Innovations in Imaging for Glioblastoma Patients

In an interview with *Curious Dr. George from Cancer Commons*, CEO Michael Schmainda, discusses how these innovations are enhancing diagnostic precision and supporting clinicians in their fight against this aggressive brain cancer. [View article](#)

Updates and Accolades Continued

New Study Highlights IB's FTB Maps as an Early Predictor for Optune Treatment

Initial findings from the Schmainda Lab at the Medical College of Wisconsin show that Imaging Biometrics' FTB maps may serve as an early indicator of response to Optune treatment for brain tumor patients. A larger study is now underway to expand on these promising results.



TOP ROW: IB Delta T1 Maps (dT1)

BOTTOM ROW: IB FTB Maps Baseline, 1-2 months and 3-4 months after starting treatment with Optune. While there is no obvious decrease in dT1 at 1-2 months, there is a clear change on FTB Maps transitioning from red to yellow early on (at 1-2 months) with confirmation of response (blue) at 3-4 months.

IB Nimble

A mobile app that allows secure collaboration amongst multi-disciplinary specialists for managing complex diseases. ANYTIME. ANYWHERE. [View video](#)



Imaging Biometrics now offers FTB Express - an Automated Workflow for IB Rad Tech

- Based upon IB Delta T1 and IB Neuro
- Quantitative classification and visualization of IB's standardized rCBV
- Output can be imported into surgical navigation systems for targeting biopsies and aiding surgical resection/treatment
- Boosts reader confidence and inter-reader agreement

[View video](#)

EXPANDED ACCESS PROGRAM UPDATE

GALLIUM MALTOLATE FOR RECURRENT GLIOBLASTOMA

We are pleased to announce the latest developments in the EAP for gallium maltolate. The EAP is designed to offer access to gallium maltolate, a novel therapeutic agent, for those who may not qualify for traditional clinical trials but are seeking innovative care options.

PROGRESS IN SITE ACTIVATION

In recent months, we have made strides in expanding the program's reach through the activation of several new clinical sites across the country. With site activations underway, our goal is to enhance patient access and generate valuable data on gallium maltolate's safety and efficacy in real-world settings. This data is essential in furthering our understanding of its therapeutic potential and in building evidence to support future FDA review processes.

ONGOING COMMITMENT TO PATIENT ACCESS

The EAP reflects our commitment to advancing treatment options for glioblastoma patients facing limited alternatives. By collaborating with leading institutions and ensuring robust site availability, we aim to deliver hope and support to patients and families impacted by this challenging condition.

We are pleased to announce that Cancer Partners of Nebraska has been added to our list of activated sites. For more details on program enrollment and site locations, please visit our website or contact us directly at eap@imagingbiometrics.com.



IB USER'S GROUP WEBINAR

TITLE:

Gallium Maltolate - New Directions for Cancer Therapy

PRESENTER:

Mona Al-Gizawiy, PhD.,
Assistant Professor Medical College of Wisconsin

OBJECTIVE:


Join us for a webinar exploring the potential of gallium maltolate in cancer therapy. This innovative metallodrug has shown promise in targeting a variety of cancers, including brain tumors such as glioblastoma and pediatric high-grade gliomas.

In this session, you'll learn:

The science behind gallium maltolate and its unique mechanism of action. Insights from preclinical studies and advancements in animal models. Current clinical trials and the roadmap for future therapeutic applications.

DATE AND TIME:

January 21, 2025, Noon CST

[REGISTER HERE](#)


MUSSELLA
 FOUNDATION FOR BRAIN TUMOR
 RESEARCH & INFORMATION, INC.

The Musella Foundation is facilitating an initiative by providing a tax-deductible donation form, enabling individuals to directly support patients in covering the costs associated with accessing gallium maltolate.

We invite you to contribute to this program by donating. Your support, regardless of the amount, will directly benefit patients with high-grade gliomas, helping them access this important treatment option.

[Donate today!](#)

Meet Dr. Mona Al-Gizawiy


SPOTLIGHT

Dr. Mona Al-Gizawiy's veterinary training and postgraduate studies provided her with the unique opportunity to engage in research that bridged clinical and laboratory work. This experience shaped her distinctive approach to translational research, particularly in cancer studies. With nearly 20 years of cancer research experience, the last 14 have been dedicated to developing gallium maltolate as a novel treatment for brain cancer.

As a researcher at the Medical College of Wisconsin, Dr. Al-Gizawiy has spearheaded the Schmainda Lab's preclinical investigations of this promising metallodrug since 2014. Her contributions have led to significant milestones, including the development of advanced animal models for brain cancer research and several FDA designations:

- Orphan Drug Designation for adult and pediatric glioblastoma (2/27/23) and pediatric Atypical Teratoid Rhabdoid Tumor (ATRT; 10/5/23)
- Fast Track Designation (10/18/23)
- Rare Pediatric Disease Designations for ATRT (5/8/24) and pediatric type diffuse high-grade glioma (5/21/24)

Dr. Al-Gizawiy's work played a pivotal role in launching a Phase 1 clinical trial of gallium maltolate for glioblastoma and serves as the foundation for an upcoming pediatric Phase 1 clinical trial targeting pediatric brain tumors scheduled for 2025. Her innovative research continues to push the boundaries of brain cancer treatment.

FOLLOW US ON



https://twitter.com/iqai_ib



<https://www.linkedin.com/company/imaging-biometrics-llc>

13416 Watertown Plank Road
 Suite 260 | Elm Grove, WI 53122
 +1.262.439.8252
 email: info@imagingbiometrics.com